SeaStar Medical Holding Corporation Common Stock Q2 2026 Earnings Recap

SeaStar Medical shares dropped 13.2% as investors reacted negatively to cautious guidance and ongoing clinical trial enrollment delays that cloud near-term revenue growth visibility.

Key Takeaways

• First quarter QUELIMMUNE net revenue increased 69% year-over-year to $495,000, driven by adoption at 7 new hospitals, on track for approximately $2 million full-year net revenue.
• Patient enrollment in the pivotal NEUTRALIZE-AKI adult trial stands at 198 of 339 planned patients, with additional clinical sites added to target end-of-year enrollment completion.
• Management emphasized continued FDA discussions on modular PMA submissions and rapid approval pathways, but progress timelines remain uncertain.
• Despite growing pediatric market presence and recognition in nephrology circles, no updated revenue guidance or acceleration signals were provided.
• The market’s negative response reflects investor concern over the pace of transitioning to the larger adult AKI opportunity and visibility on margin or profitability improvements.